MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Preliminary data suggest people with Group 1 pulmonary hypertension had improved outcomes if they had ever received hormone replacement therapy.
An administration change in November could see the return of closed borders or increased protections for immigrants.
Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.
Immigrant children need a variety of resources when they come to the United States.
HPV vaccine uptake increased almost 20% under guidance from the clinic-based program.
Discrimination, fear and lack of knowledge are just a few of the obstacles they face when trying to access healthcare.
The American Thoracic Society (ATS) has recommended moving to race-neutral equations for assessing what lung functions mean. A study presented at the ATS meeting this weekend projected how the new equation would affect disease classification, lung test standards for becoming a firefighter and VA disability benefits.
Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation.
Breast cancer stats from the American Association for Cancer Research 2024 Cancer Disparities Report.
A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.
Results from the phase 3 NOTUS trial presented at the ATS meeting confirm benefits of Dupixent (dupilumab) among 20% to 40% of people with chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.
Pamrevlumab is the third investigational agent to fail in a phase 3 trials. Researchers said It may be time to stop treating idiopathic pulmonary fibrosis as a single disease and treat subcategories organized by relevant biomarkers.
The update was prompted by a recent increase in breast cancer cases among women in their 40s.
The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Debra Boyer, M.D., M.H.P.E., discussed the program of the 2024 American Thoracic Society International Conference in San Diego and the limits of artificial intelligence.
Set to launch this summer, Uber Caregiver is tailored specifically for caregivers and their loved ones, aiming to tackle challenges head on and enhance the overall care experience.
According to findings collected by Cedars-Sinai, artificial intelligence can reduce serious health risks associated with pregnancy and childbirth, and improve screening for some gynecological cancers.
But the waivers that allow for coverage of tele-health expire at the end the year. Several bills have been put forth to extend coverage.
The authors of an article about relatively low biosimilar use by people with inflammatory bowel disease have suggestions for how to mitigage the nocebo effect.
The efforts to prevent one disease increased another, likely due to the lack of methadone and sterile needles.
The Biotechnology Innovation Organization has some suggestions, including "platform designation" by FDA and changes at the CDC.
The FDA has approved six with dermatologic indications and more are in late-stage trials.
Home testing for fecal calprotectin, a commonly used marker in IBD diagnosis, and symptom quetionnaires might hasten the diagnosis of inflammatory bowel disease.
Enrollment has soared, but a relatively modest 2025 rate increase and changes to the Star rating system may lead plans to cut back on with their benefit offerings.
Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.
This month's episode of the Meet the Board podcast features a new member of our editorial advisory board, Marci J. Chodroff, MD, FACP, vice president of Medical Affairs at Magellan Rx Management, a Prime Therapeutics company.
Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.
